Pulling SEC filings + quote and writing the call…

CorMedix Inc.
Next earnings Aug 5, 2026 · consensus $0.24 EPS, $97.5M rev
Last earnings +5.7% on 2026-05-14
Revenue grew 617.0% YoY.
Quality fundamentals and an attractive price line up (~824% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0001410098, latest 10-Q filed 2026-05-14) · EODHD · as of 6/25/2026, 11:40:30 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
CorMedix Inc. shows $312M in FY2025 revenue (+617.0% YoY), a 52.3% net margin, and 40.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $191K | $65.4K | — | $43.5M | $312M |
| Gross profit | $42.0K | $61.7K | — | $40.3M | $276M |
| Operating income | -$29.4M | -$30.6M | -$49.0M | -$22.4M | $150M |
| Net income | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163M |
| Diluted EPS | -$0.75 | -$0.74 | -$0.91 | -$0.30 | $2.04 |
| Net margin | -14774.7% | -45409.9% | — | -41.2% | 52.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1075 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-02-04 | Zelnick Kaufman Beth Chief Legal Officer | Award | 36.0K | |
| 2026-02-04 | Hurlburt Elizabeth Chief Operating Officer | Award | 36.0K | |
| 2026-02-04 | Todisco Joseph Chief Executive Officer | Award | 77.2K | |
| 2026-01-26 | Kaplan Myron Director | Award | 30.5K | |
| 2026-01-23 | Blum Susan Chief Financial Officer | Award | 72.8K | |
| 2026-01-23 | Blum Susan Chief Financial Officer | Tax | 9.77K @ $7.27 | $71.0K |
| 2026-01-23 | Zelnick Kaufman Beth Chief Legal Officer | Award | 72.8K | |
| 2026-01-23 | Zelnick Kaufman Beth Chief Legal Officer | Tax | 8.80K @ $7.27 | $64.0K |
| 2026-01-23 | Hurlburt Elizabeth Chief Operating Officer | Award | 93.0K | |
| 2026-01-23 | Hurlburt Elizabeth Chief Operating Officer | Tax | 10.8K @ $7.27 | $78.4K |
| 2026-01-23 | Todisco Joseph Chief Executive Officer | Award | 226K | |
| 2026-01-23 | Todisco Joseph Chief Executive Officer | Tax | 27.3K @ $7.27 | $199K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.